5-(Chloromethyl)-3-methyl-1H-1,2,4-triazole hydrochloride | 1609404-00-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-(Chloromethyl)-3-methyl-1H-1,2,4-triazole hydrochloride
• 英文别名: 3-(chloromethyl)-5-methyl-1H-1,2,4-triazole;hydrochloride
• CAS: 1609404-00-3
• 化学式: C4H7Cl2N3
• mdl: MFCD28024723
• 分子量: 168.02
• InChiKey: SFNDQQRCRPMLIO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.93
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  41.6
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• Pyrazolo-triazine derivatives as ligands for gaba receptors
  申请人：——

  公开号：US20030060467A1

  公开（公告）日：2003-03-27

  A class of substituted pyrazolo[1,5-d][1,2,4]triazine derivatives, possessing an optionally substituted cycloalkyl, phenyl or heteroaryl substituent at the 7-position, an alkyl group at the 4-position, and a substituted alkoxy moiety at the 2-position, are selective ligands for GABA A receptors, in particular having high affinity for the &agr;2 and/or &agr;3 subunit thereof, and are accordingly of benefit in the treatment and/or prevention of disorders of the central nervous system, including anxiety and convulsions.

  一类取代吡唑并[1,5-d][1,2,4]三嗪衍生物，其在7位具有可选择的取代环烷基、苯基或杂环烷基取代基，在4位具有烷基基团，在2位具有取代烷氧基团，是GABAA受体的选择性配体，特别是具有高亲和力的α2和/或α3亚基，因此在治疗和/或预防中枢神经系统疾病，包括焦虑和抽搐方面具有益处。
• PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS
  申请人：Genentech, Inc.

  公开号：EP2448941A2

  公开（公告）日：2012-05-09
• [EN] PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS<br/>[FR] COMPOSÉS PYRAZOLOPYRIMIDINE INHIBITEURS DES JAK ET PROCÉDÉS
  申请人：GENENTECH INC

  公开号：WO2011003065A2

  公开（公告）日：2011-01-06

  A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient are disclosed.